| Cell line name | MDA-MB-231 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | MDA_MB_231; MDA-MB 231; MDA.MB.231; MDA MB 231; MDA MB231; MDA Mb231; MDA-MB231; MDAMB-231; MDAMB231; MDA-231; MDA-231P; MDA231; MDA231-BRE; MB231; MD Anderson-Metastatic Breast-231 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accession | BTCC-1100 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Resource Identification Initiative | To cite this cell line use: MDA-MB-231 (BTCC-1100) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Comments | Group: Triple negative breast cancer (TNBC) cell line. Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). Part of: COSMIC cell lines project. Part of: ENCODE project common cell types; tier 3. Part of: GrayJW breast cancer cell line panel. Part of: ICBP43 breast cancer cell line panel. Part of: JFCR39 cancer cell line panel. Part of: JFCR45 cancer cell line panel. Part of: KuDOS 95 cell line panel. Part of: MD Anderson Cell Lines Project. Part of: NCI-60 cancer cell line panel. Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12532. Registration: Chiron Master Culture Collection; CMCC 10583 (CMCC #10583). Population: Caucasian. Doubling time: 1.3 days (PubMed=9671407); 26.7 hours (PubMed=9815641); 24.7 hours (PubMed=24389870); 36.2 hours (PubMed=34238275); 38 hours (ATCC=HTB-26); ~25-30 hours (DSMZ=ACC-732); 41.9 hours (NCI-DTP=MDA-MB-231); ~38 hours (PBCF); 31.43 hours (GrayJW panel). Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger). Omics: Array-based CGH. Omics: Chromatin accessibility by ATAC-seq. Omics: Cell surface proteome. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep proteome analysis. Omics: Deep quantitative proteome analysis. Omics: DNA methylation analysis. Omics: Exosome proteome analysis. Omics: Fluorescence phenotype profiling. Omics: Glycoproteome analysis by proteomics. Omics: H2BK120ub ChIP-seq epigenome analysis. Omics: H3K4me3 ChIP-seq epigenome analysis. Omics: H3K23ac ChIP-seq epigenome analysis. Omics: H3K27ac ChIP-seq epigenome analysis. Omics: H3K27me3 ChIP-seq epigenome analysis. Omics: H3K36me3 ChIP-seq epigenome analysis. Omics: H3K4me1 ChIP-seq epigenome analysis. Omics: H3K4me3 ChIP-seq epigenome analysis. Omics: H3K79me2 ChIP-seq epigenome analysis. Omics: H3K9ac ChIP-seq epigenome analysis. Omics: H3K9me3 ChIP-seq epigenome analysis. Omics: H4K8ac ChIP-seq epigenome analysis. Omics: lncRNA expression profiling. Omics: Metabolome analysis. Omics: miRNA expression profiling. Omics: N-glycan profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: Secretome proteome analysis. Omics: SNP array analysis. Omics: Transcriptome analysis by microarray. Omics: Transcriptome analysis by RNAseq. Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870). Misspelling: MDA-MB-321; Note=Occasionally. Misspelling: MDA-MD-231; Cosmic=1071900; Cosmic=1176602. Misspelling: MDA-321; GEO=GSM459713. Misspelling: MDA-MG-231; PubMed=6582512. Misspelling: MD-MB-231; PRIDE=PXD010634. Misspelling: MD-MBA-231; Note=Occasionally. Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sequence variations |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HLA typing | Source: PubMed=77569
Source: PubMed=15748285
Source: PubMed=25960936
Source: PubMed=26589293
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Genome ancestry | Source: PubMed=30894373
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Disease | Breast adenocarcinoma (NCIt: C5214) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Species of origin | Homo sapiens (Human) (NCBI Taxonomy: 9606) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hierarchy | Children:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sex of cell | Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Age at sampling | 51Y | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Category | Cancer cell line | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| STR profile | Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; Genomics_Center_BCF_Technion; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200; PubMed=28889351 Markers:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cell line collections (Providers) | AddexBio; C0006002/58 ATCC; HTB-26 ATCC; CRM-HTB-26 BCRC; 60425 BCRJ; 0164 CCTCC; GDC0297 CLS; 300275 - Discontinued DSMZ; ACC-732 ECACC; 92020424 IBRC; C10684 ICLC; HTL99004 IZSLER; BS TCL 223 KCB; KCB 200776YJ KCLB; 30026 NCBI_Iran; C578 NCI-DTP; MDA-MB-231 |
|---|---|
| Chemistry resources | ChEMBL-Cells; CHEMBL3307960 ChEMBL-Targets; CHEMBL400 GDSC; 905960 PharmacoDB; MDAMB231_900_2019 PubChem_Cell_line; CVCL_0062 |
| Encyclopedic resources | Wikidata; Q17577870 |
| Experimental variables resources | EFO; EFO_0001209 |
PubMed=31092827; DOI=10.1038/s41467-019-10148-6
Liu K., Newbury P.A., Glicksberg B.S., Zeng W.Z.-D., Paithankar S., Andrechek E.R., Chen B.
Evaluating cell lines as models for metastatic breast cancer through integrative analysis of genomic data.
Nat. Commun. 10:2138.1-2138.12(2019)
PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)
PubMed=32782317; DOI=10.1038/s41598-020-70393-4
Risha Y., Minic Z., Ghobadloo S.M., Berezovski M.V.
The proteomic analysis of breast cell line exosomes reveals disease patterns and potential biomarkers.
Sci. Rep. 10:13572-13572(2020)
PubMed=34238275; DOI=10.1186/s12885-021-08511-2
Samson J., Derlipanska M., Zaheed O., Dean K.
Molecular and cellular characterization of two patient-derived ductal carcinoma in situ (DCIS) cell lines, ETCC-006 and ETCC-010.
BMC Cancer 21:790.1-790.20(2021)
PubMed=34320349; DOI=10.1016/j.celrep.2021.109441
Jochems F., Thijssen B., De Conti G., Jansen R., Pogacar Z., Groot K., Wang L.-Q., Schepers A., Wang C., Jin H.-J., Beijersbergen R.L., Leite de Oliveira R., Wessels L.F.A., Bernards R.
The cancer SENESCopedia: a delineation of cancer cell senescence.
Cell Rep. 36:109441.1-109441.22(2021)
PubMed=35042871; DOI=10.1038/s41523-021-00379-6
Rypens C., Bertucci F., Finetti P., Robertson F.M., Fernandez S.V., Ueno N.T., Woodward W.A., Van Golen K., Vermeulen P., Dirix L., Viens P., Birnbaum D., Devi G.R., Cristofanilli M., Van Laere S.
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.
NPJ Breast Cancer 8:12.1-12.12(2022)
PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)
